Endovasc Inc. Announces Agreement With ABC Labs To Develop Liprostin Assays For Phase III Trial

HOUSTON--(BUSINESS WIRE)--June 27, 2006--ENDOVASC INC. (OTCBB:EVSC - News), today announced that the Company has awarded ABC Laboratories a contract to develop an assay to determine the content of Prostaglandin E-1 (PGE-1) in the blood of patients during and post delivery of Liprostin. The pharmakokinetic studies will be carried out in parallel with the Liprostin Phase III studies. Currently, there is no validated analytical study on record in the U.S. to determine the concentration of both PGE-1 and its active metabolite at concentrations that Endovasc expects to see in the bloodstream.